8-K
filed June 24, 2024, 7:59 PM ET
CIK 0001828522
other material
confidence high
sentiment negative
materiality 1.00
eFFECTOR Therapeutics to wind down operations, terminate staff, and delist from Nasdaq
eFFECTOR Therapeutics, Inc.
- Company terminated all employees in connection with a planned wind down of operations.
- Expects one-time charges of approximately $0.6 million for severance and related costs in Q2 2024.
- All seven directors resigned; Stephen Worland (CEO), Michael Byrnes (CFO), and Douglas Warner (CMO) departed.
- Craig Jalbert appointed sole director, CEO, President, Treasurer, and Secretary to manage wind down.
- Company plans to voluntarily request delisting of common stock and warrants from Nasdaq.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Craig R. Jalbert was appointed as sole member of the Board at eFFECTOR Therapeutics, Inc..
- Action
- appointed
- Role
- sole member of the Board
Exact text from the filing
On June 21, 2024, the Board appointed Craig R. Jalbert, age 62, as the Company’s CEO, President, Treasurer and Secretary, and sole member of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Elizabeth P. Bhatt resigned as Director at eFFECTOR Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Michael Byrnes departed as Chief Financial Officer and Secretary at eFFECTOR Therapeutics, Inc..
- Action
- ceased serving
- Role
- Chief Financial Officer and Secretary
Exact text from the filing
On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Stephen T. Worland, Ph.D. resigned as Director at eFFECTOR Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Brian M. Gallagher, Jr., Ph.D. resigned as Director at eFFECTOR Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Chris Ehrlich resigned as Director at eFFECTOR Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Craig R. Jalbert was appointed as CEO, President, Treasurer and Secretary at eFFECTOR Therapeutics, Inc..
- Action
- appointed
- Role
- CEO, President, Treasurer and Secretary
Exact text from the filing
On June 21, 2024, the Board appointed Craig R. Jalbert, age 62, as the Company’s CEO, President, Treasurer and Secretary, and sole member of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Barbara Klencke, M.D. resigned as Director at eFFECTOR Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Caroline Loewy resigned as Director at eFFECTOR Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Stephen T. Worland, Ph.D. departed as President and CEO at eFFECTOR Therapeutics, Inc..
- Action
- ceased serving
- Role
- President and CEO
Exact text from the filing
On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Kristen Harrington-Smith resigned as Director at eFFECTOR Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Douglas Warner, M.D. departed as Chief Medical Officer at eFFECTOR Therapeutics, Inc..
- Action
- ceased serving
- Role
- Chief Medical Officer
Exact text from the filing
On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.